Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR‐mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: Kudo, Kenichiro, Ohashi, Kadoaki, Makimoto, Go, Higo, Hisao, Kato, Yuka, Kayatani, Hiroe, Kurata, Yasuko, Takami, Yoichiro, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Sato, Akiko, Hotta, Katsuyuki, Yoshino, Tadashi, Tanimoto, Mitsune, Kiura, Katsuyuki
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467494/
https://ncbi.nlm.nih.gov/pubmed/28388009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12063
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi